WO2005070447A3 - M-csf muteins and uses thereof - Google Patents

M-csf muteins and uses thereof Download PDF

Info

Publication number
WO2005070447A3
WO2005070447A3 PCT/US2005/001630 US2005001630W WO2005070447A3 WO 2005070447 A3 WO2005070447 A3 WO 2005070447A3 US 2005001630 W US2005001630 W US 2005001630W WO 2005070447 A3 WO2005070447 A3 WO 2005070447A3
Authority
WO
WIPO (PCT)
Prior art keywords
csf
csf muteins
muteins
methods
screening
Prior art date
Application number
PCT/US2005/001630
Other languages
French (fr)
Other versions
WO2005070447A2 (en
Inventor
Deborah Lee Zimmerman
Gregory Martin Harrowe
Cheng Liu
Kirston Koths
William Michael Kavanaugh
Li Long
Original Assignee
Chiron Corp
Deborah Lee Zimmerman
Gregory Martin Harrowe
Cheng Liu
Kirston Koths
William Michael Kavanaugh
Li Long
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Deborah Lee Zimmerman, Gregory Martin Harrowe, Cheng Liu, Kirston Koths, William Michael Kavanaugh, Li Long filed Critical Chiron Corp
Priority to JP2006551223A priority Critical patent/JP2007524671A/en
Priority to EP05726267A priority patent/EP1706137A2/en
Publication of WO2005070447A2 publication Critical patent/WO2005070447A2/en
Publication of WO2005070447A3 publication Critical patent/WO2005070447A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

M-CSF muteins are provided, along with pharmaceutical compositions containing a M-CSF mutein, kits containing a pharmaceutical composition, methods of preventing and treating bone metastases in a subject afflicted with metastatic cancer, and methods of screening for M-CSF muteins.
PCT/US2005/001630 2004-01-21 2005-01-21 M-csf muteins and uses thereof WO2005070447A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006551223A JP2007524671A (en) 2004-01-21 2005-01-21 M-CSF muteins and uses thereof
EP05726267A EP1706137A2 (en) 2004-01-21 2005-01-21 M-csf muteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53798504P 2004-01-21 2004-01-21
US60/537,985 2004-01-21

Publications (2)

Publication Number Publication Date
WO2005070447A2 WO2005070447A2 (en) 2005-08-04
WO2005070447A3 true WO2005070447A3 (en) 2005-12-08

Family

ID=34807153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001630 WO2005070447A2 (en) 2004-01-21 2005-01-21 M-csf muteins and uses thereof

Country Status (3)

Country Link
EP (1) EP1706137A2 (en)
JP (1) JP2007524671A (en)
WO (1) WO2005070447A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150383A1 (en) * 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
TWI595008B (en) 2010-05-04 2017-08-11 戊瑞治療有限公司 Antibodies that bind csf1r
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201501413YA (en) 2012-08-31 2015-03-30 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
BR112015008255B1 (en) 2012-10-12 2023-02-28 Inbiomotion S.L IN VITRO METHODS FOR DIAGNOSIS OR PROGNOSIS OF BONE METASTASIS IN AN INDIVIDUAL WITH PROSTATE CANCER AND METHOD FOR CLASSIFIING AN INDIVIDUAL SUFFERING FROM PROSTATE CANCER IN A COHORT
CN106795222A (en) 2014-06-23 2017-05-31 戊瑞治疗有限公司 With the method for the Antybody therapy symptom for combining colony-stimulating factor 1 acceptor (CSF1R)
ES2851390T3 (en) 2014-10-29 2021-09-06 Five Prime Therapeutics Inc Combination therapy for cancer
KR20170096187A (en) 2014-12-22 2017-08-23 파이브 프라임 테라퓨틱스, 인크. Anti-csf1r antibodies for treating pvns
RS61531B1 (en) 2015-04-13 2021-04-29 Five Prime Therapeutics Inc Combination therapy for cancer
JP2020535119A (en) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク Combination therapy of anti-CSF1R and anti-PD-1 antibody for pancreatic cancer
CN111246876A (en) * 2017-10-27 2020-06-05 弗吉尼亚联邦大学 Compositions comprising MDA-7/IL-24 protein and methods of use
CN112843082B (en) * 2021-02-02 2022-07-05 四川大学 Application of DNA tetrahedron in preparation of medicine for treating diabetes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001942A1 (en) * 1988-08-19 1990-03-08 Genetics Institute, Inc. Treatment for malignant melanoma
WO1998039449A1 (en) * 1997-03-04 1998-09-11 Chiron Corporation COMPOSITIONS AND USE OF M-CSF-alpha
EP0955056A1 (en) * 1990-08-23 1999-11-10 Chiron Corporation Recombinant colony stimulating factor-1 for treatment of fungal infection
EP0955365A2 (en) * 1992-06-09 1999-11-10 Chiron Corporation Crystallization of M-CSF
JP2001233784A (en) * 2000-02-23 2001-08-28 Morinaga Milk Ind Co Ltd Interleukin-18 production promoter
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001942A1 (en) * 1988-08-19 1990-03-08 Genetics Institute, Inc. Treatment for malignant melanoma
EP0955056A1 (en) * 1990-08-23 1999-11-10 Chiron Corporation Recombinant colony stimulating factor-1 for treatment of fungal infection
EP0955365A2 (en) * 1992-06-09 1999-11-10 Chiron Corporation Crystallization of M-CSF
WO1998039449A1 (en) * 1997-03-04 1998-09-11 Chiron Corporation COMPOSITIONS AND USE OF M-CSF-alpha
JP2001233784A (en) * 2000-02-23 2001-08-28 Morinaga Milk Ind Co Ltd Interleukin-18 production promoter
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200171, Derwent World Patents Index; Class B04, AN 2001-613857, XP002347324 *
MIYAMOTO TAKESHI ET AL: "Differentiation and function of osteoclasts.", THE KEIO JOURNAL OF MEDICINE. MAR 2003, vol. 52, no. 1, March 2003 (2003-03-01), pages 1 - 7, XP002347322, ISSN: 0022-9717 *

Also Published As

Publication number Publication date
EP1706137A2 (en) 2006-10-04
WO2005070447A2 (en) 2005-08-04
JP2007524671A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2005070447A3 (en) M-csf muteins and uses thereof
WO2004045532A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
IL231810A (en) Maytansinoid derivatives and pharmaceutical compositions containing the same, methods of producing the same and methods of use thereof for use in treating cancer
IL191938A (en) Bicyclic heteroaryl compounds, pharmaceutical compositions comprising them and bicyclic heteroaryl compounds for use in treating cancer
EP1737809A4 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2004034990A3 (en) Methods and compositions for use in treating cancer
IL179140A (en) Mixture of antibody-drug conjugate compounds, pharmaceutical composition for the treatment of cancer comprising it and a method of making the mixture
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
EP1718310A4 (en) Methods and compositions for treating tumors and metastatic disease
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
IL178822A (en) 4-phenylamino-quinazolin-6-yl-amides, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments for the treatment of proliferative disorders
IL181752A0 (en) Polymer blend and compositions and methods for using the same
IL169500A0 (en) Pyrrolopyridazine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL179714A (en) Pharmaceutical composition comprising derivatives of 2-biphenyl-4-yl-2,3-dihydro-1h-quinazolin-4-one and use thereof in the manufacture of medicaments for treating cancer and angiogenesis
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
IL176919A0 (en) Methods and compositions for treating cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
IL178939A (en) Dual and triple combinations suitable for the synergistic treatment of breast cancer, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments or as medicaments for the treatment of breast cancer
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2007076160A3 (en) C-10 carbamates of taxanes
EP1747228A4 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006551223

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005726267

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005726267

Country of ref document: EP